Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CGEM vs VOR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VOR Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–2 Matrix Metrics)

VOR Overall Winner 6-Pillar Tally: CGEM 2 – 3 VOR (1 Tie) Matrix Metrics: CGEM 2 – 5 VOR

As of Nov 16, 2026, Vor Biopharma Inc. (VOR) is the stronger overall head-to-head candidate over Cullinan Therapeutics, Inc. (CGEM) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). CGEM carries a Unified Composite Score of 41.0/100 (SELL) at $9.50 (6.7x Forward P/E, 0.0% operating margin), whereas VOR carries 57.8/100 (HOLD) at $18.97 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: CGEM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.9); meanwhile VOR trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CGEM vs VOR
CGEM NASDAQ
Cullinan Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$9.50
-7.59% 1D
Market Cap $667.4M
TTM Revenue N/A
Forward P/E 6.7x
Beta / 30D Vol 1.59β · 105% Vol
Unified Composite Score
41.0 / 100 SELL
Tech 25.0 Fund 51.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.2%), weak momentum, RSI 29
RSI-14: 28.9 · SMA20: $13.21 · SMA50: $15.62
VOR NASDAQ Head-to-Head Winner
Vor Biopharma Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$18.97
-2.32% 1D
Market Cap $1.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.90β · 61% Vol
Unified Composite Score
57.8 / 100 HOLD
Tech 50.0 Fund 55.0 Flow 66.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.4 · SMA20: $19.48 · SMA50: $19.87

6-Pillar Scorecard Institutional Category Breakdown (CGEM 2 – 3 VOR)

Columns: Metric · CGEM · VOR
1. Valuation Multiples CGEM
Forward P/E 6.7x N/M
Trailing P/E 6.7x 0.1x
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale VOR
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $667.4M $1.2B
3. Profitability & Quality CGEM
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -55.5% -125.4%
4. Balance Sheet & Cash Flow VOR
Cash Generation (TTM) N/A -$1.63B
Cash Flow Margin N/A N/A
Net Cash / Leverage $4.33 Book/Sh · -55.5% ROE $1.04B Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VOR
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 124.5% (9th %ile) 120.2% (6th %ile)
Put/Call OI Skew N/A 2.03x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CGEM (2) vs VOR (5)
Institutional Metric CGEM VOR Criterion Row Edge
Market Capitalization
Scale
$667.4M $1.2B Larger Scale VOR
Trailing P/E Ratio
Valuation
6.7x 0.1x Lower Multiple VOR
Forward P/E Ratio
Valuation
6.7x N/M Lower Multiple CGEM
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-55.5% -125.4% Higher ROE CGEM
52-Week Range Position
Momentum
10% ($8–$23) 64% ($6–$26) Stronger Trend VOR
Beta / 30D Volatility
Risk Regime
1.59β · 105% Vol 1.90β · 61% Vol Lower Realized Risk VOR
Unified Institutional Score
Composite Signal
41.0 / 100 (SELL) 57.8 / 100 (HOLD) Higher Composite VOR
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($4.33 Book/Sh · -55.5% ROE) -$1.63B ($1.04B Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VOR +31.74 pp
CGEM: -26.53% · VOR: +5.21%
3M Horizon VOR +35.9 pp
CGEM: -54.41% · VOR: -18.51%
6M Horizon VOR +70.36 pp
CGEM: -36.11% · VOR: +34.25%
1Y Horizon VOR +79.69 pp
CGEM: +14.87% · VOR: +94.56%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CGEM vs VOR. Trailing 12-month operating profitability (CGEM 0.0% vs VOR 0.0%) and valuation multiples (CGEM 6.7x vs VOR N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CGEM ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-55.5% · 6.7x
VOR ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-125.4% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CGEM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 124.5%
IV Percentile 9th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CGEM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VOR CONSOLIDATION
52d in phase · OBV NEUTRAL
Current IV 120.2%
IV Percentile 6th %ile
Put/Call OI Skew 2.03x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact VOR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CGEM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $667.4M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
VOR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CGEM vs VOR Key Questions & Quantitative Answers

As of Nov 16, 2026, Vor Biopharma Inc. (VOR) is the stronger overall head-to-head candidate over Cullinan Therapeutics, Inc. (CGEM) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). CGEM carries a Unified Composite Score of 41.0/100 (SELL) at $9.50 (6.7x Forward P/E, 0.0% operating margin), whereas VOR carries 57.8/100 (HOLD) at $18.97 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: CGEM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.9); meanwhile VOR trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VOR leads the Growth & Scale pillar: CGEM posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with VOR at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, CGEM generates N/A in USD-normalized revenue versus N/A for VOR. In operating R&D and SG&A reinvestment, CGEM deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VOR.

CGEM screens cheaper on headline valuation multiples. CGEM trades at 6.7x Forward P/E, 6.7x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas VOR trades at N/M Forward P/E, 0.1x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CGEM (-55.5% ROE) versus VOR (-125.4% ROE) capital efficiency.

In options market volatility and institutional positioning, CGEM carries 124.5% implied volatility (9th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.59β · 105% Vol realized risk). By comparison, VOR carries 120.2% implied volatility (6th %ile, Compressed (<25th %ile)), a 2.03x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.90β · 61% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.